Relapsed plasmablastic lymphoma in a HIV‐negative patient: Pushing the envelope

Abstract

Abstract This case emphasizes that, with the availability of novel immunotherapy agents (Daratumumab), and repurposed use of bortezomib, a patient with HIV‐negative relapsed PBL can be treated successfully and consolidated with an allogeneic haploidentical hematopoietic cell transplantation.

Keywords

• daratumumab
• haploidentical transplantation
• novel therapies
• plasmablastic lymphoma
• relapse